ArticleScientific reports2025
Glial cells are involved in day-night protein dysregulation in the hippocampus of a mouse model of Alzheimer's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The hippocampus regulates memory and cognition, both of which are influenced by circadian rhythms. These rhythms also drive time-dependent gene expression in neurons and glial cells, affecting hippocampal function. In Alzheimer's disease (AD), alterations in these rhythms, contributing to cognitive decline, is little understood. This study examined hippocampal proteomes from 7-month-old wild-type (WT) and 3xTgAD mice at two time points (Zeitgeber 2, ZT2 and ZT14) to detect early pathological changes. In WT mice, 199 proteins (8%) showed diurnal variation, particularly those linked to energy metabolism and neuronal/glial functions. In 3xTgAD mice, this rhythmic variation dropped by half (3.6%), with only five proteins shared across genotypes. Moreover, significant differences in protein expression emerged between WT and 3xTgAD at both time points, notably involving mitochondrial function, oxidative phosphorylation, and ATP production. Functional clustering revealed disrupted bioenergetic pathways, especially affecting complex I of the electron transport chain and astrocytic metabolism. These early alterations suggest a breakdown in daily control of hippocampal energy regulation in AD. The results highlight the critical role of sampling time in research and suggest that circadian disruption in astrocytic and neuronal metabolism may play a central role in AD progression and could inform future chronotherapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.